Guess which small cap ASX stock is rocketing 80% today

What is getting investors excited on Wednesday? Let's find out.

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

LBT Innovations Limited (ASX: LBT) shares are having a very strong session on Wednesday.

At one stage today, the small cap ASX stock was up as much as 80% to 2.7 cents.

It has since pulled back but remains up 40% to 2.1 cents at the time of writing.

Why is this small cap ASX stock rocketing?

Investors have been fighting to get hold of the medical technology company's shares following the release of a promising announcement.

According to the release, the company has signed an agreement to sell five Automated Plate Assessment System (APAS) Independence instruments to global giant AstraZeneca (LSE: AZN). It will also provide annual maintenance and support services over seven years.

APAS Independence is described as a best-in-class technology that uses artificial intelligence and machine learning software to automate the imaging, analysis, and interpretation of microbiology culture plates.

It is the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through its subsidiary Clever Culture Systems (CCS).

Contract value

According to the release, the total contract value is estimated to be between US$2.2 million and US$2.7 million, which is the equivalent of A$3.4 million to A$4.1 million.

The final contract value will depend on the level of maintenance and support services selected by AstraZeneca. Though, the majority of the contract value is to be received as the instruments are installed, which is scheduled over the next six months.

But it may not stop there. Management notes that there's potential for additional orders to follow.

It also feels that the rollout is indicative of how other companies might consider adoption of the APAS technology, and highlights that it has created a strong pipeline of opportunities within this customer segment, including some of the largest global pharmaceutical companies.

Management commentary

The small cap ASX stock's CEO and managing director, Brent Barnes, was pleased with the agreement. He said:

The purchasing agreement demonstrates the value the APAS technology provides and unlocks an initial roll-out of five instruments across a number of their large manufacturing operations. This decision was made based on demonstrated performance of the technology within the AstraZeneca manufacturing processes and provides credibility for the technology more broadly.

This milestone provides evidence and confidence that the APAS Independence is a fully validated technology that meets the stringent requirements for environmental monitoring during drug manufacturing, applicable to all customers globally for this application. Pleasingly, evaluations with additional multinational pharmaceutical customers are expected to commence in the current quarter.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended AstraZeneca Plc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »